Psychotic Disorders Clinical Trial
Official title:
Instruments Validation and Correlational Explorations Between Clinical Recovery and Personal Recovery for the Evaluation of a Brief Intervention by Peer Support Workers in the Province of Quebec, Canada
Several instruments have been developed by clinicians and academics specialized in mental health and psychiatry to assess clinical recovery in terms of symptom reduction. Based on their life narratives, measurement tools have also been developed and validated through participatory research programs by persons living with mental health problems or illnesses to assess a more personal experience of recovery as a way of leaving a meaningful and satisfying life despite and beyond ongoing disorders and symptoms of mental illness. Other instruments have also been developed to assess the degree to which mental health and psychiatric institutions are recovery-oriented. The overall aim of this project is to explore correlations between clinical recovery, personal recovery and this latter organizational recovery.
The "signatures" of mental health problems or illnesses (MHPIs) is a term formulated by the
National Institute of Mental Health (NIMH) to designate the broad range of genetic,
biological, psychological, and social factors that may "sign" a specific mental disorder,
depending on an individual's sex, history, lifestyle habits, and so on. In 2010, the Research
Center of the Mental Health University Institute of Montreal (IUSMM) decided to develop the
"Signature Bank" project for the collection of biological and dimensional signatures from all
patients with MHPIs of the IUSMM (catchment area of about 600,000 inhabitants). Over 4,000
patients are treated annually at the IUSMM, while an additional 2,000 patients per year are
treated by means of outpatient or ambulatory services. These activities provide us with one
of the largest populations of psychiatric patients in Canada. This research project is based
on the extensive involvement of the IUSMM-hospital site in the attempt to establish an
exclusive niche for discoveries in the signatures of mental illnesses. By collaborating with
the Research Centre, IUSMM-hospital managers have contributed to the implementation of this
large-scale project that aims at measuring the genetic, biological, psychological, and social
signatures of people living with MHPIs who use the IUSMM-hospital's clinical services, and
who consent to taking part in this longitudinal research initiative. The goal of is study is
to better understand not only the signatures of MHPIs, but that of recovery in mental health,
and as reported by patients living with psychiatric disorders who will additionally fill out
the French Recovery Assessment Scale (RAS), Recovery Self-Assessment (RSA) and Citizenship
Measure (CM). Participants in the Signature Bank are routinely approached and recruited by a
Research Nurse at their admission to the Psychiatric Emergency Department (T1) of the IUSMM.
As of March 2019, 1862 eligible participants from the psychiatric emergency of the IUSMM have
been approached. Of this number, 1218 agreed to participate and thus completed at least T1 of
the Signature study. For all participants, the same measures are repeated at discharge (T2),
at the first follow up at an outpatient clinic (T3), and finally (T4) when treatment ends or
12 months after T3. Our sample is characterized by individuals with psychotic disorders
(N=166), or mood disorders (N=186), for a total of 352 patients who completed T3 and/or T4.
All participants signed a detailed consent form, and the study was approved by the local
ethics committee in accordance with the Declaration of Helsinki. Research Nurses collected
patient's psychiatric diagnoses from medical records. They were established by psychiatrists
on the ward, and coded according to the World Health Organisation International
Classification of Disease (ICD-10). This study will use 2 of the categories of mental or
behavioural disorder (F00-F99): 1) Schizophrenia and psychotic disorders (F20-F29), and 2)
Mood disorders (F30-F39) who have enrolled in the Signature Bank for longitudinal studies and
who have thus already completed questionnaires for clinical evaluation purposes (clinical
recovery). Those who accept to participate in this study will further complete the RAS, the
CM, and the RSA, which was developed to gauge the degree to which programs implement
recovery-oriented practices and to identify strengths and areas of improvement as agencies
strive to offer recovery-oriented care. Two specific research objectives are pursued.
Firstly: measuring correlational relations between dimensions of personal recovery (RAS and
CM), and levels of anxiety, depression, dependence, psychosis, and social functioning
(clinical recovery). Secondly: validation of the psychometric properties of the French
version of the RSA (organizational recovery). Statistical analyses will be performed to
determine internal consistency (Cronbach alphas for each of the subscales), and construct
validity (confirmatory or exploratory factor analyzes). Our power calculation has determined
that 200 participants will be needed to test measurement invariance for sex and main
psychiatric diagnosis (psychotic or mood disorders) in order to detect significant
correlations with a Type I error of 5% and a power of 80%. Signature Bank participants will
be contacted to complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items,
5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale).
These participants have already completed these other measures (clinical recovery):
iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression:
Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol
Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse
Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire
(PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment
Schedule (WHODAS 2.0) (12 items).
Each patient diagnosed with F20-F39 disorders and who have completed at least T2 will be
contacted by phone and asked to additionally fill out the RSA, RAS and CM. Those who will
accept to be contacted will be invited to come to the IUSMM where they will be met by a
Research Assistant. They will first read and sign the additional Information and Consent Form
specific to this study or ask further questions before doing so. Secondly, they will fill out
the RSA, RAS and CM on a touch screen device. Data will be stored on the Signature Bank
secured server. If necessary, future new participants who will have completed T2 will be
contacted in the same way until the required number of participants is reached. There are
typically 60 to 80 new participants per month to the Signature Bank. Test-retest reliability
will be investigated, as well as internal consistency, construct validity of these RSA, RAS
and CM tools, correlations between their subscales and those of anxiety, depression,
substance misuse, psychosis, and social functioning measures, in and across psychiatric
diagnoses, and sex. The same i-iv measures will be used in a future project to assess the
effect of a brief intervention by Peer Support Workers (PSW) with a control group. A
Randomized Control Trial with future IUSMM patients who will have accepted to be enrolled in
the Signature Bank will be proposed to compare treatment as usual to treatment as usual plus
the PSW intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130676 -
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |